旨在评估基于多参数 MRI (mp-MRI) 的膀胱影像报告和数据系统 (VI-RADS) 评分是否可以预测膀胱癌 (BCa) 复发。 在这项回顾性研究中，2011 年 11 月至 2011 年 11 月至 2011 年 11 月期间，284 名经病理证实患有膀胱肿瘤的患者入组。 2020 年 10 月也包括在内。两名放射科医生根据 VI-RADS 对 mp-MRI 扫描进行盲目且独立的评分。评分不一致的问题得到一致解决。最近一次随访于2022年12月完成。采用Pearson相关分析、独立样本t检验和受试者操作特征分析来评估VI-RADS评分对1至5年复发预测的有效性。根据最新的随访情况，有 37 人（共 284 人，占 13.0%）、69 人（共 284 人，占 24.3%）、70 人（共 234 人，占 29.9%）、72 人（共 190 人，占 37.9%）和 63 人（共 135 人，占 46.7%） %) 患者分别在 1 至 5 年的随访中出现癌症复发。 VI-RADS 评分显示，在 1 至 4 年的监测期间，复发病例和非复发病例之间存在显着的组间差异 (p<0.05)。与 VI-RADS 评分为 3、4 或 5 的患者相比，VI-RADS 评分为 1 或 2 的患者的无复发生存率显着更高 (p<0.05)。 1至5年复发预测的受试者工作特征曲线下面积分别为0.744、0.686、0.656、0.595和0.536。 VI-RADS评分≥3分是1年复发评估的阈值，VI-RADS≥3分是2年复发预测的分界点。VI-RADS评分在术前预测BCa复发方面具有潜力，但其预测能力随着时间的推移而降低。VI-RADS 在膀胱癌复发评估方面具有潜力，但其预后价值随着时间的推移而降低。 VI-RADS≥≥3 的患者术后 1 或 2 年内复发的可能性更大，因此应进行强化监测。• VI-RADS 评分在 1 至 4 年复发和非复发患者组中存在显着差异。 • VI-RADS 评分 ≤ 2 的患者表现出更有利的无复发生存结果。 • VI-RADS 评分对于膀胱癌复发预测的预后价值随着时间的推移而降低。© 2023。作者，获得欧洲放射学会的独家许可。

To evaluate whether Vesical Imaging-Reporting And Data System (VI-RADS) scores based on multiparametric MRI (mp-MRI) can predict bladder cancer (BCa) recurrence.In this retrospective study, 284 patients with pathologically confirmed bladder neoplasms from November 2011 to October 2020 were included. Two radiologists blindly and independently scored mp-MRI scans according to VI-RADS. Scoring inconsistency was resolved in consensus. The latest follow-up was completed in December 2022. Pearson's correlation analyses, independent-sample t-tests, and receiver operating characteristic analyses were performed to assess the efficacy of VI-RADS score for the 1- to 5-year recurrence prognostication.Based on the latest follow-up, 37 (of 284, 13.0%), 69 (of 284, 24.3%), 70 (of 234, 29.9%), 72 (of 190, 37.9%), and 63 (of 135, 46.7%) patients had cancer recurrence at 1- to 5-year follow-up, respectively. VI-RADS scores showed significantly intergroup differences between recurrent and nonrecurrent cases during 1- to 4-year surveillance (p < 0.05). The recurrence-free survival was significantly higher in patients with VI-RADS scores of 1 or 2, compared to those with scores of 3, 4, or 5 (p < 0.05). Areas under the receiver operating characteristic curves for 1- to 5-year recurrence prediction were 0.744, 0.686, 0.656, 0.595, and 0.536, respectively. VI-RADS score of 3 or more was the threshold for 1-year recurrence assessment, and VI-RADS more than 3 was the cutoff for 2-year recurrence prediction.VI-RADS score has potential in preoperative prognostication of BCa recurrence, but its predictive power decreases over time.VI-RADS has potential in bladder cancer recurrence assessment, but its prognostic value decreases over time. Patients with VI-RADS ≥ 3 may be more likely to recur in 1 or 2 years postoperatively, thus should be performed with intensive surveillances.• VI-RADS scores had significant differences in 1- to 4-year recurrent and nonrecurrent patient groups. • Patients with VI-RADS scores of ≤ 2 showed more favorable recurrence-free survival outcomes. • The prognostic value of VI-RADS score decreased over time for bladder cancer recurrence prediction.© 2023. The Author(s), under exclusive licence to European Society of Radiology.